Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Cytosorbents (CTSO) Receivables - Net (2016 - 2025)

Cytosorbents' Receivables - Net history spans 15 years, with the latest figure at $7.6 million for Q4 2025.

  • Quarterly results put Receivables - Net at $7.6 million for Q4 2025, up 3.14% from a year ago — trailing twelve months through Dec 2025 was $7.6 million (up 3.14% YoY), and the annual figure for FY2025 was $7.6 million, up 3.14%.
  • Receivables - Net for Q4 2025 was $7.6 million at Cytosorbents, up from $7.4 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $7.8 million in Q2 2024 to a low of $4.5 million in Q4 2021.
  • The 5-year median for Receivables - Net is $6.1 million (2023), against an average of $6.2 million.
  • Peak annual rise in Receivables - Net hit 47.92% in 2021, while the deepest fall reached 12.32% in 2021.
  • Year by year, Receivables - Net stood at $4.5 million in 2021, then rose by 25.24% to $5.7 million in 2022, then rose by 6.92% to $6.1 million in 2023, then grew by 20.85% to $7.3 million in 2024, then increased by 3.14% to $7.6 million in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $7.6 million, $7.4 million, and $7.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.